-Reuters
Ambrx Biopharma’s ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE:AMAM) have announced the selection of Ambrx’s antibody-drug conjugate (ADC) ARX788 for a new…